Legend Biotech shares are trading higher after the company announced a positive CHMP opinion for CARVYKTI for the treatment of patients with relapsed and lenalidomide refractory multiple myeloma in earlier lines of therapy.
Portfolio Pulse from Benzinga Newsdesk
Legend Biotech's shares are trading higher following the announcement of a positive CHMP opinion for CARVYKTI, aimed at treating patients with relapsed and lenalidomide refractory multiple myeloma in earlier lines of therapy.
February 23, 2024 | 5:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Legend Biotech's stock is experiencing an uptick due to the positive CHMP opinion on CARVYKTI for treating multiple myeloma.
The positive CHMP opinion is a significant regulatory milestone for Legend Biotech, indicating a strong endorsement of CARVYKTI's efficacy and safety for treating multiple myeloma. This news directly impacts the company's stock as it enhances investor confidence in the company's pipeline and potential market expansion. The immediate positive reaction in stock price reflects the market's optimistic view on the drug's commercial success and its contribution to Legend Biotech's growth.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100